BHVN and PRTG Related Headlines
Go Back- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
- Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therap
- Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
- Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
- Biohaven Pharma (BHVN) Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass
- Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
- Biohaven Pharma (BHVN) Announces $200M Proposed Public Offering Of Common Shares
- BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
- Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
- Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Stu
- Biohaven Pharma's (BHVN) Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
- Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
- Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments
- Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
- Biohaven Pharma (BHVN) Provides Preliminary EEG Data Update for Kv7 Platform
- Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
- Biohaven Pharma (BHVN) Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
- Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
- Biohaven to Present R&D Day at Yale School of Management
- Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
- Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
BHVN and PRTG Related Press Releases
Go Back- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
- Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therap
- Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
- Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
- Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
- BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
- Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
- Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Stu
- Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
- Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
- Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
- Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
- Biohaven to Present R&D Day at Yale School of Management
- Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
- Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
BHVN and PRTG Related SEC Filings
Go Back- Form 8-K Biohaven Ltd. For: Apr 15
- Form 4 Biohaven Ltd. For: Apr 05 Filed by: Coric Vlad
- Form 4 Biohaven Ltd. For: Apr 05 Filed by: CHILDS JOHN W
- Form DEFA14A Biohaven Ltd.
- Form DEF 14A Biohaven Ltd. For: Apr 30
- Form 8-K Biohaven Ltd. For: Mar 12
- Form 424B7 Biohaven Ltd.
- Form 4 Biohaven Ltd. For: Mar 08 Filed by: Coric Vlad
- Form 4 Biohaven Ltd. For: Mar 08 Filed by: CHILDS JOHN W
- Form 10-K Biohaven Ltd. For: Dec 31
- Form 8-K Biohaven Ltd. For: Feb 29
- Form SC 13G/A Biohaven Ltd. Filed by: Point72 Asset Management, L.P.
- Form SC 13G/A Biohaven Ltd. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
- Form SC 13G/A Biohaven Ltd. Filed by: JANUS HENDERSON GROUP PLC
- Form SC 13G Biohaven Ltd. Filed by: BlackRock Inc.
- Form SC 13G/A Biohaven Ltd. Filed by: STATE STREET CORP
- Form 4 Biohaven Ltd. For: Jan 08 Filed by: CHILDS JOHN W
- Form 4 Biohaven Ltd. For: Jan 08 Filed by: Coric Vlad
- Form 8-K Biohaven Ltd. For: Jan 08
- Form 4 Biohaven Ltd. For: Jan 02 Filed by: Car Bruce
- Form 4 Biohaven Ltd. For: Jan 02 Filed by: Clark George C.
- Form 4 Biohaven Ltd. For: Jan 02 Filed by: Coric Vlad
- Form 4 Biohaven Ltd. For: Jan 02 Filed by: Buten Matthew
- Form 4 Biohaven Ltd. For: Jan 02 Filed by: Gentile Kimberly
- Form 4 Biohaven Ltd. For: Dec 29 Filed by: Antonijevic Irina
- Form 144 Biohaven Ltd. Filed by: Antonijevic Irina
- Form 8-K Biohaven Ltd. For: Nov 14
- Form 10-Q Biohaven Ltd. For: Sep 30
- Form 4 Biohaven Ltd. For: Nov 02 Filed by: Buten Matthew
- Form 4 Biohaven Ltd. For: Nov 02 Filed by: Clark George C.
- Form 4 Biohaven Ltd. For: Nov 02 Filed by: Coric Vlad
- Form 4 Biohaven Ltd. For: Nov 02 Filed by: Gentile Kimberly
- Form 4 Biohaven Ltd. For: Nov 02 Filed by: Car Bruce
- Form SC 13G Biohaven Ltd. Filed by: Point72 Asset Management, L.P.
- Form 4 Biohaven Ltd. For: Oct 05 Filed by: CHILDS JOHN W
- Form 4 Biohaven Ltd. For: Oct 05 Filed by: Coric Vlad
- Form 4 Biohaven Ltd. For: Oct 05 Filed by: Buten Matthew
- Form 4 Biohaven Ltd. For: Oct 04 Filed by: Bailey Gregory
- Form 8-K Biohaven Ltd. For: Oct 05
- Form 424B5 Biohaven Ltd.
- Form 8-K Biohaven Ltd. For: Oct 02
- Form 424B5 Biohaven Ltd.
- Form 424B5 Biohaven Ltd.
- Form S-3ASR Biohaven Ltd.
- Form 8-K Biohaven Ltd. For: Sep 27
- Form 4 Biohaven Ltd. For: Aug 30 Filed by: CHILDS JOHN W
- Form 4 Biohaven Ltd. For: Aug 04 Filed by: CHILDS JOHN W
- Form 10-Q Biohaven Ltd. For: Jun 30
- Form 8-K Biohaven Ltd. For: Jul 31
- Form 8-K Biohaven Ltd. For: Jul 27
- Form 8-K Biohaven Ltd. For: May 31
- Form 8-K Biohaven Ltd. For: May 12
- Form S-8 Biohaven Ltd.
- Form 10-Q Biohaven Ltd. For: Mar 31
- Form 4 Biohaven Ltd. For: May 02 Filed by: Mehta Kishan
- Form 4 Biohaven Ltd. For: May 02 Filed by: Bailey Gregory
- Form 4 Biohaven Ltd. For: May 02 Filed by: Heffernan Michael Thomas
- Form 4 Biohaven Ltd. For: May 02 Filed by: CHILDS JOHN W
- Form 4 Biohaven Ltd. For: May 02 Filed by: Antonijevic Irina
- Form 4 Biohaven Ltd. For: May 02 Filed by: GREGORY JULIA P
- Form 4 Biohaven Ltd. For: May 02 Filed by: HUGIN ROBERT J
- Form 8-K Biohaven Ltd. For: May 02
